| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695264 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
Adjuvant bevacizumab with dose-dense chemotherapy is associated with acceptable toxicity and a high likelihood of completing 4Â cycles of therapy. Dynamic changes in Flt-3L may represent a predictive marker to treatment response.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Nicole D. Fleming, Robert L. Coleman, Celestine Tung, Shannon N. Westin, Wei Hu, Yunjie Sun, Priya Bhosale, Mark F. Munsell, Anil K. Sood,